메뉴 건너뛰기




Volumn 18, Issue 10, 2016, Pages

Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome

Author keywords

Atherosclerosis; Diabetes mellitus; Dyslipidemia; Hypertension; Metabolic syndrome

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; NEW DRUG;

EID: 84991052058     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-016-0683-0     Document Type: Review
Times cited : (59)

References (63)
  • 3
    • 0031014495 scopus 로고    scopus 로고
    • Small LDL, atheogenic dyslipidemia and the metabolic syndrome
    • COI: 1:STN:280:DyaK2s7kslKgsQ%3D%3D, PID: 8994405, Defines atherogenic dyslipidemia and highlights the role of dyslipidemia in relation to cardiovascular events.
    • Grundy SM. Small LDL, atheogenic dyslipidemia and the metabolic syndrome. Circulation. 1997;95:1–4. Defines atherogenic dyslipidemia and highlights the role of dyslipidemia in relation to cardiovascular events.
    • (1997) Circulation , vol.95 , pp. 1-4
    • Grundy, S.M.1
  • 4
    • 84876808529 scopus 로고    scopus 로고
    • Immunity, atherosclerosis and cardiovascular disease
    • PID: 23635324
    • Frostegard J. Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013;11:117.
    • (2013) BMC Med , vol.11 , pp. 117
    • Frostegard, J.1
  • 5
    • 84155172981 scopus 로고    scopus 로고
    • The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation
    • COI: 1:CAS:528:DC%2BC3MXhs12htL7E, PID: 22104117
    • Wang J, Razuvaev A, Folkersen L, et al. The expression of IGFs and IGF binding proteins in human carotid atherosclerosis, and the possible role of IGF binding protein-1 in the regulation of smooth muscle cell proliferation. Atherosclerosis. 2012;220:102–9.
    • (2012) Atherosclerosis , vol.220 , pp. 102-109
    • Wang, J.1    Razuvaev, A.2    Folkersen, L.3
  • 6
    • 84874885965 scopus 로고    scopus 로고
    • Update on acute coronary syndromes: the pathologists’ view
    • COI: 1:CAS:528:DC%2BC3sXjslKhsLo%3D, PID: 23242196
    • Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists’ view. Eur Heart J. 2013;34:719–28.
    • (2013) Eur Heart J , vol.34 , pp. 719-728
    • Falk, E.1    Nakano, M.2    Bentzon, J.F.3    Finn, A.V.4    Virmani, R.5
  • 7
    • 11144355354 scopus 로고    scopus 로고
    • Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid-lowering with statins after acute coronary syndrome
    • COI: 1:CAS:528:DC%2BD2cXjtVeqtr8%3D, PID: 15007110
    • Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid-lowering with statins after acute coronary syndrome. N Engl J Med. 2004;350(15):1495–504.
    • (2004) N Engl J Med , vol.350 , Issue.15 , pp. 1495-1504
    • Cannon, C.P.1    Braunwald, E.2    McCabe, C.H.3
  • 8
    • 84908149085 scopus 로고    scopus 로고
    • Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia
    • PID: 25277610
    • Van Wijk DF, Sjouke B, Figueroa A, et al. Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. J Am Coll Cardiol. 2014;64:1418–26.
    • (2014) J Am Coll Cardiol , vol.64 , pp. 1418-1426
    • Van Wijk, D.F.1    Sjouke, B.2    Figueroa, A.3
  • 9
    • 33645103550 scopus 로고    scopus 로고
    • Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
    • COI: 1:CAS:528:DC%2BD28Xislequr8%3D, PID: 16554528, One of the original studies correlating lower LDL levels with mutations in PCSK9, with significant reductions in cardiovascular risk.
    • Cohen JC, Boerwinkle E, Mosley Jr TH, Hoobs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72. One of the original studies correlating lower LDL levels with mutations in PCSK9, with significant reductions in cardiovascular risk.
    • (2006) N Engl J Med , vol.354 , pp. 1264-1272
    • Cohen, J.C.1    Boerwinkle, E.2    Mosley, T.H.3    Hoobs, H.H.4
  • 10
    • 84915819121 scopus 로고    scopus 로고
    • Inactivating mutations in NPC1L1 and protection from coronary heart disease
    • The Myocardial Infarction Genetics Consortium Investigators. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med. 2014;371:2072–82.
    • (2014) N Engl J Med , vol.371 , pp. 2072-2082
    • The Myocardial Infarction Genetics Consortium Investigators1
  • 11
    • 33847252897 scopus 로고    scopus 로고
    • Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study
    • PID: 17283263
    • Lloyd-Jones DM, Liu K, Colangelo LA, et al. Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the Coronary Artery Risk Development in Young Adults Study. Circulation. 2007;115:1004–11.
    • (2007) Circulation , vol.115 , pp. 1004-1011
    • Lloyd-Jones, D.M.1    Liu, K.2    Colangelo, L.A.3
  • 12
    • 0037148922 scopus 로고    scopus 로고
    • Obesity
    • COI: 1:CAS:528:DC%2BD38XhsFOjsr4%3D, PID: 11856799
    • Yanovski SZ, Yanovski JA. Obesity. N Engl J Med. 2002;346:591–602.
    • (2002) N Engl J Med , vol.346 , pp. 591-602
    • Yanovski, S.Z.1    Yanovski, J.A.2
  • 13
    • 25844457693 scopus 로고    scopus 로고
    • Obesity
    • PID: 16198769
    • Haslam DW, James WPT. Obesity. Lancet. 2005;366:1197–209.
    • (2005) Lancet , vol.366 , pp. 1197-1209
    • Haslam, D.W.1    James, W.P.T.2
  • 14
    • 84991102596 scopus 로고    scopus 로고
    • U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans—2010. Accessed at on 26 Jan. 2016.
    • U.S. Department of Agriculture and U.S. Department of Health and Human Services. Dietary Guidelines for Americans—2010. Accessed at http://www.cnpp.usda.gov/dietary-guidelines-2010 on 26 Jan. 2016.
  • 15
    • 84991054213 scopus 로고    scopus 로고
    • Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Accessed at on 26 January 2016.
    • Scientific Report of the 2015 Dietary Guidelines Advisory Committee. Accessed at http://www.health.gov/dietaryguidelines/2015-scientific-report/ on 26 January 2016.
  • 16
    • 4544288392 scopus 로고    scopus 로고
    • Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial
    • COI: 1:CAS:528:DC%2BD2cXnvFGisbY%3D, PID: 15383514
    • Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292:1440–6.
    • (2004) JAMA , vol.292 , pp. 1440-1446
    • Esposito, K.1    Marfella, R.2    Ciotola, M.3
  • 17
    • 36048986007 scopus 로고    scopus 로고
    • Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort
    • PID: 17712023
    • Tortosa A, Bes-Rastrollo M, Sanchez-Villegas A, et al. Mediterranean diet inversely associated with the incidence of metabolic syndrome: the SUN prospective cohort. Diabetes Care. 2007;30:2957–9.
    • (2007) Diabetes Care , vol.30 , pp. 2957-2959
    • Tortosa, A.1    Bes-Rastrollo, M.2    Sanchez-Villegas, A.3
  • 18
    • 0037034257 scopus 로고    scopus 로고
    • Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
    • COI: 1:CAS:528:DC%2BD38XhtVWqurc%3D, PID: 11832527
    • Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.
    • (2002) N Engl J Med , vol.346 , pp. 393-403
    • Knowler, W.C.1    Barrett-Connor, E.2    Fowler, S.E.3
  • 19
    • 0038677039 scopus 로고    scopus 로고
    • Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity)
    • PID: 12821592
    • Thompson PD, Buchner D, Pina IL, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity). Circulation. 2003;107:3109–16.
    • (2003) Circulation , vol.107 , pp. 3109-3116
    • Thompson, P.D.1    Buchner, D.2    Pina, I.L.3
  • 20
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
    • Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.
    • (2010) Lancet , vol.376 , pp. 1670-1681
    • Cholesterol Treatment Trialists’ (CTT) Collaboration1    Baigent, C.2    Blackwell, L.3    Emberson, J.4
  • 21
    • 84864832599 scopus 로고    scopus 로고
    • The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials
    • Cholesterol Treatment Trialists’ Collaboration, Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–90.
    • (2012) Lancet , vol.380 , pp. 581-590
    • Cholesterol Treatment Trialists’ Collaboration1    Mihaylova, B.2    Emberson, J.3    Blackwell, L.4
  • 22
    • 3142729178 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program ATP III guidelines
    • PID: 15249516
    • Grundy SM, Cleeman JI, Merz CN, Brewer Jr HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program ATP III guidelines. Circulation. 2004;110(2):227–39.
    • (2004) Circulation , vol.110 , Issue.2 , pp. 227-239
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3    Brewer, H.B.4    Clark, L.T.5    Hunninghake, D.B.6
  • 23
    • 0037126526 scopus 로고    scopus 로고
    • Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
    • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–421.
    • (2002) Circulation , vol.106 , pp. 3143-3421
  • 24
    • 84893935789 scopus 로고    scopus 로고
    • An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report
    • The International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia.
    • Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia—full report. J Clin Lipidol. 2014;8:29–60. The International Atherosclerosis Society has developed a new set of recommendations for the management of dyslipidemia.
    • (2014) J Clin Lipidol , vol.8 , pp. 29-60
    • Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel members1
  • 25
    • 84897970506 scopus 로고    scopus 로고
    • A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
    • 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Current evidence based guidelines for management of hyperlipidemia from ACC/AHA.
    • 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45. Current evidence based guidelines for management of hyperlipidemia from ACC/AHA.
    • (2014) Circulation , vol.129 , pp. S1-S45
  • 26
    • 84960878943 scopus 로고    scopus 로고
    • Standards of medical care in diabetes—2016
    • Document outlining current recommended management goals for diabetes mellitus.
    • American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016;39 suppl 1:S1–106. Document outlining current recommended management goals for diabetes mellitus.
    • (2016) Diabetes Care , vol.39 , pp. S1-S106
    • American Diabetes Association1
  • 27
    • 84904490497 scopus 로고    scopus 로고
    • Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomized controlled trials including 117,411 patients
    • Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomized controlled trials including 117,411 patients. BMJ. 2014;349:g4379.
    • (2014) BMJ , vol.g4379 , pp. 349
    • Keene, D.1    Price, C.2    Shun-Shin, M.J.3    Francis, D.P.4
  • 28
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • Correction in N Engl J Med. 2012;367:189
    • AIM-HIGH Investigators, Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–67. Correction in N Engl J Med. 2012;367:189.
    • (2011) N Engl J Med , vol.365 , pp. 2255-2267
    • AIM-HIGH Investigators1    Boden, W.E.2    Probstfield, J.L.3    Anderson, T.4
  • 29
    • 84904252744 scopus 로고    scopus 로고
    • Effects of extended-release niacin with laropiprant in high-risk patients
    • Definitive study which shows ineffectiveness of niacin therapy on improving cardiovascular outcomes along with significant increases in the rates of serious adverse events with addition of niacin therapy.
    • HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203–12. Definitive study which shows ineffectiveness of niacin therapy on improving cardiovascular outcomes along with significant increases in the rates of serious adverse events with addition of niacin therapy.
    • (2014) N Engl J Med , vol.371 , Issue.3 , pp. 203-212
    • HPS2-THRIVE Collaborative Group1
  • 30
    • 33644873843 scopus 로고    scopus 로고
    • Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
    • COI: 1:CAS:528:DC%2BD2MXht1Cqt7%2FK, PID: 16316964
    • Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005;112:3375–83.
    • (2005) Circulation , vol.112 , pp. 3375-3383
    • Pischon, T.1    Girman, C.J.2    Sacks, F.M.3    Rifai, N.4    Stampfer, M.J.5    Rimm, E.B.6
  • 31
    • 46449096115 scopus 로고    scopus 로고
    • Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment
    • COI: 1:CAS:528:DC%2BD1cXmsFymu7g%3D, PID: 18519851
    • Kastelein JJ, van der Steeg WA, Holme I, TNT Study Group, IDEAL Study Group, et al. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. Circulation. 2008;117:3002–9.
    • (2008) Circulation , vol.117 , pp. 3002-3009
    • Kastelein, J.J.1    van der Steeg, W.A.2    Holme, I.3    TNT Study Group, IDEAL Study Group,4
  • 32
    • 84926191670 scopus 로고    scopus 로고
    • Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
    • COI: 1:CAS:528:DC%2BC2MXotFGlsbc%3D, PID: 25773378, Phase 3 study of newly released biologic PCSK9 inhibitor alirocumab.
    • Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489–99. Phase 3 study of newly released biologic PCSK9 inhibitor alirocumab.
    • (2015) N Engl J Med , vol.372 , Issue.16 , pp. 1489-1499
    • Robinson, J.G.1    Farnier, M.2    Krempf, M.3    Bergeron, J.4    Luc, G.5    Averna, M.6
  • 33
    • 0032515775 scopus 로고    scopus 로고
    • Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UKPDS 23
    • COI: 1:STN:280:DyaK1c3htVKhsg%3D%3D, PID: 9549452
    • Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UKPDS 23. BMJ. 1998;316:823–8.
    • (1998) BMJ , vol.316 , pp. 823-828
    • Turner, R.C.1    Millns, H.2    Neil, H.A.3    Stratton, I.M.4    Manley, S.E.5    Matthews, D.R.6
  • 34
    • 0037840242 scopus 로고    scopus 로고
    • MCR/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebo-controlled trial
    • Heart Protection Study Collaborative Group. MCR/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomized placebo-controlled trial. Lancet. 2003;361:2005–16.
    • (2003) Lancet , vol.361 , pp. 2005-2016
    • Heart Protection Study Collaborative Group1
  • 35
    • 4344683381 scopus 로고    scopus 로고
    • Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial
    • COI: 1:CAS:528:DC%2BD2cXmvFWltrY%3D, PID: 15325833
    • Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685–96.
    • (2004) Lancet , vol.364 , pp. 685-696
    • Colhoun, H.M.1    Betteridge, D.J.2    Durrington, P.N.3    Hitman, G.A.4    Neil, H.A.5    Livingstone, S.J.6
  • 36
    • 2542507788 scopus 로고    scopus 로고
    • Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)
    • COI: 1:CAS:528:DyaK1MXjslCmtLc%3D, PID: 10335771
    • Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999;83:1497–9.
    • (1999) Am J Cardiol , vol.83 , pp. 1497-1499
    • Sposito, A.C.1    Mansur, A.P.2    Coelho, O.R.3
  • 37
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT
    • Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT. JAMA. 2002;288(23):2981–97.
    • (2002) JAMA , vol.288 , Issue.23 , pp. 2981-2997
    • Officers and Coordinators for the ALLHAT Collaborative Research Group1
  • 38
    • 24644443331 scopus 로고    scopus 로고
    • Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial
    • PID: 16154016
    • Dahlof B, Sever PS, Poulter NR, for the ASCOT Investigators, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet. 2005;366:895–906.
    • (2005) Lancet , vol.366 , pp. 895-906
    • Dahlof, B.1    Sever, P.S.2    Poulter, N.R.3    for the ASCOT Investigators4
  • 39
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular event in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
    • COI: 1:STN:280:DC%2BD3c%2Fpt1emug%3D%3D, PID: 10639539
    • Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular event in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–53.
    • (2000) N Engl J Med , vol.342 , pp. 145-153
    • Yusuf, S.1    Sleight, P.2    Pogue, J.3
  • 40
    • 0037160968 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol
    • COI: 1:CAS:528:DC%2BD38XisV2htrw%3D, PID: 11937178
    • Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995–1003.
    • (2002) Lancet , vol.359 , Issue.9311 , pp. 995-1003
    • Dahlof, B.1    Devereux, R.B.2    Kjeldsen, S.E.3
  • 41
    • 77951473452 scopus 로고    scopus 로고
    • Effect of valsartan on the incidence of diabetes and cardiovascular events
    • NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362(16):1463–76.
    • (2010) N Engl J Med , vol.362 , Issue.16 , pp. 1463-1476
    • NAVIGATOR Study Group1
  • 44
    • 0038818552 scopus 로고    scopus 로고
    • Blockade of the rennin-angiotensin system increases adiponectin concentrations in patients with essential hypetenstion
    • COI: 1:CAS:528:DC%2BD3sXkvVKmtrc%3D, PID: 12796280
    • Furuhashi M, Ura N, Higashiura K, et al. Blockade of the rennin-angiotensin system increases adiponectin concentrations in patients with essential hypetenstion. Hypertension. 2003;42:76–81.
    • (2003) Hypertension , vol.42 , pp. 76-81
    • Furuhashi, M.1    Ura, N.2    Higashiura, K.3
  • 45
    • 33748047823 scopus 로고    scopus 로고
    • Role of the renin-angiotensin-aldosterone system in the metabolic syndrome
    • PID: 16929137
    • Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contrib Nephrol. 2006;151:122–34.
    • (2006) Contrib Nephrol , vol.151 , pp. 122-134
    • Engeli, S.1
  • 46
    • 0036945863 scopus 로고    scopus 로고
    • Metabolic benefits associated with sibutramine therapy
    • COI: 1:CAS:528:DC%2BD38XptFCisbc%3D
    • Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obesit. 2002;26 Suppl 4:S34–7.
    • (2002) Int J Obesit , vol.26 , pp. S34-S37
    • Krejs, G.J.1
  • 47
    • 77956284607 scopus 로고    scopus 로고
    • Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects
    • COI: 1:CAS:528:DC%2BC3cXhtFWjsrnN, PID: 20818901
    • James WP, Caterson ID, Coutinho W, SCOUT Investigators, et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010;363:905–17.
    • (2010) N Engl J Med , vol.363 , pp. 905-917
    • James, W.P.1    Caterson, I.D.2    Coutinho, W.3    SCOUT Investigators4
  • 48
    • 0030853476 scopus 로고    scopus 로고
    • Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine
    • COI: 1:STN:280:DyaK2szpvVartg%3D%3D, PID: 9271482, Published correction appears in: N Engl J Med 1997;337:1483
    • Mark EJ, Patalas ED, Chang HT, et al. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N Engl J Med. 1997;337:602–6. Published correction appears in: N Engl J Med 1997;337:1483.
    • (1997) N Engl J Med , vol.337 , pp. 602-606
    • Mark, E.J.1    Patalas, E.D.2    Chang, H.T.3
  • 49
    • 0030876952 scopus 로고    scopus 로고
    • Valvular heart disease associated with fenfluraminephentermine
    • COI: 1:CAS:528:DyaK2sXmtVGntLc%3D, PID: 9271479, Published correction appears in: N Engl J Med 1997;337:1783
    • Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluraminephentermine. N Engl J Med. 1997;337:581–8. Published correction appears in: N Engl J Med 1997;337:1783.
    • (1997) N Engl J Med , vol.337 , pp. 581-588
    • Connolly, H.M.1    Crary, J.L.2    McGoon, M.D.3
  • 50
    • 5444251860 scopus 로고    scopus 로고
    • The orlistat and cardiovascular risk profile in patients with the metabolic syndrome and type 2 diabetes (ORLICARDIA) study
    • COI: 1:CAS:528:DC%2BD2cXhtVSlur%2FN, PID: 15383188
    • Didangelos TP, Thanapoulou AK, Bousboulas SH, et al. The orlistat and cardiovascular risk profile in patients with the metabolic syndrome and type 2 diabetes (ORLICARDIA) study. Curr Med Res Opin. 2004;20:1393–401.
    • (2004) Curr Med Res Opin , vol.20 , pp. 1393-1401
    • Didangelos, T.P.1    Thanapoulou, A.K.2    Bousboulas, S.H.3
  • 51
    • 1042303480 scopus 로고    scopus 로고
    • Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study or orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients
    • COI: 1:CAS:528:DC%2BD2cXmvV2jug%3D%3D, PID: 14693982
    • Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study or orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27:155–61.
    • (2004) Diabetes Care , vol.27 , pp. 155-161
    • Torgerson, J.S.1    Hauptman, J.2    Boldrin, M.N.3    Sjostrom, L.4
  • 52
    • 34247898951 scopus 로고    scopus 로고
    • The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism—or inverse agonism—as potential obesity treatment and other therapeutic use
    • COI: 1:CAS:528:DC%2BD2sXmvVWmsL4%3D, PID: 17489873
    • Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, et al. The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism—or inverse agonism—as potential obesity treatment and other therapeutic use. J Clin Pharm Ther. 2007;32(3):209–31.
    • (2007) J Clin Pharm Ther , vol.32 , Issue.3 , pp. 209-231
    • Xie, S.1    Furjanic, M.A.2    Ferrara, J.J.3    McAndrew, N.R.4    Ardino, E.L.5    Ngondara, A.6
  • 53
    • 33847359549 scopus 로고    scopus 로고
    • Rimonabant: a novel selective cannabinoid—1 receptor antagonist for treatment of obesity
    • COI: 1:CAS:528:DC%2BD2sXjsF2nsbw%3D, PID: 17322160
    • Patel PN, Pathak R. Rimonabant: a novel selective cannabinoid—1 receptor antagonist for treatment of obesity. Am J Health Syst Pharm. 2007;64(5):481–9.
    • (2007) Am J Health Syst Pharm , vol.64 , Issue.5 , pp. 481-489
    • Patel, P.N.1    Pathak, R.2
  • 54
    • 84894874002 scopus 로고    scopus 로고
    • Management of obesity and cardiometabolic risk—role of phentermine/extended release topiramate
    • COI: 1:CAS:528:DC%2BC2cXhs1GjsrfE
    • Sweeting AN, Tabet E, Caterson ID, et al. Management of obesity and cardiometabolic risk—role of phentermine/extended release topiramate. Diab Metab Synd Obes. 2014;7:35–44.
    • (2014) Diab Metab Synd Obes , vol.7 , pp. 35-44
    • Sweeting, A.N.1    Tabet, E.2    Caterson, I.D.3
  • 55
    • 84862207266 scopus 로고    scopus 로고
    • Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
    • COI: 1:CAS:528:DC%2BC38Xos1Wkurs%3D
    • Astrup A, Carraro R, Finer N, NN8022- 1807 Investigators, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond). 2012;36:843–54.
    • (2012) Int J Obes (Lond) , vol.36 , pp. 843-854
    • Astrup, A.1    Carraro, R.2    Finer, N.3    NN8022- 1807 Investigators4
  • 56
    • 77956904326 scopus 로고    scopus 로고
    • Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial
    • COI: 1:CAS:528:DC%2BC3cXhs1Wkt7zF
    • Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19:110–20.
    • (2011) Obesity (Silver Spring) , vol.19 , pp. 110-120
    • Wadden, T.A.1    Foreyt, J.P.2    Foster, G.D.3
  • 58
    • 84991057863 scopus 로고    scopus 로고
    • Rockville, MD: U.S
    • U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. FDA Briefing Document NDA 200063 Contrave (Naltrexone 4 mg, 8 mg/Bupropion HCL 90 mg extended release tablet). 2010 Advisory Committee—December 7, 2010. Rockville, MD: U.S. Food and Drug Administration; 2010.
    • (2010) Food and Drug Administration , pp. 2010
  • 59
    • 84879324574 scopus 로고    scopus 로고
    • A randomized, phase 3 trial of naltrexone SR/ bupropion SR on weight and obesity-related risk factors (COR-II)
    • COI: 1:CAS:528:DC%2BC3sXpvFaksL0%3D
    • Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/ bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21:935–43.
    • (2013) Obesity (Silver Spring) , vol.21 , pp. 935-943
    • Apovian, C.M.1    Aronne, L.2    Rubino, D.3
  • 60
    • 84891869792 scopus 로고    scopus 로고
    • Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes
    • COI: 1:CAS:528:DC%2BC3sXhvFaksLvM, PID: 24144653
    • Hollander P, Gupta AK, Plodkowski R, COR-Diabetes Study Group, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36:4022–9.
    • (2013) Diabetes Care , vol.36 , pp. 4022-4029
    • Hollander, P.1    Gupta, A.K.2    Plodkowski, R.3    COR-Diabetes Study Group4
  • 61
    • 77956057548 scopus 로고    scopus 로고
    • Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial
    • COI: 1:CAS:528:DC%2BC3cXhtVGmtbbK, PID: 20673995
    • Greenway FL, Fujioka K, Plodkowski RA, COR-I Study Group, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet. 2010;376:595–605.
    • (2010) Lancet , vol.376 , pp. 595-605
    • Greenway, F.L.1    Fujioka, K.2    Plodkowski, R.A.3    COR-I Study Group4
  • 62
    • 84859003663 scopus 로고    scopus 로고
    • Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and metaanalyses of randomised controlled trials
    • PID: 22236411
    • Vilsbøll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and metaanalyses of randomised controlled trials. BMJ. 2012;344:d7771.
    • (2012) BMJ , vol.344 , pp. d7771
    • Vilsbøll, T.1    Christensen, M.2    Junker, A.E.3
  • 63
    • 84886946727 scopus 로고    scopus 로고
    • Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome Results (LEADER) trial
    • COI: 1:CAS:528:DC%2BC3sXhsFGru7jL, PID: 24176437, Liraglutide in the management of diabetes mellitus and weight loss.
    • Marso SP, Poulter NR, Nissen SE, LEADER Trial Investigators, et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome Results (LEADER) trial. Am Heart J. 2013;166:823–30. Liraglutide in the management of diabetes mellitus and weight loss.
    • (2013) Am Heart J , vol.166 , pp. 823-830
    • Marso, S.P.1    Poulter, N.R.2    Nissen, S.E.3    LEADER Trial Investigators4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.